Tobacco Settlement Spending Plans in Ashes

Why is it that smoking--so expensive, personally injurious, and detrimental to the public purse--is still an essential part of daily life for so many of us? The primary answer is craving: Smoking is more reinforcing than crack cocaine. Teasing out the factors--psychological, neurological, and genetic--that contribute to nicotine dependence is a complex process, as we report on page 21. But the potential payoffs from new treatments in terms of health benefits (and developer profits) guarantees

Written byRichard Gallagher
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Why is it that smoking--so expensive, personally injurious, and detrimental to the public purse--is still an essential part of daily life for so many of us? The primary answer is craving: Smoking is more reinforcing than crack cocaine.

Teasing out the factors--psychological, neurological, and genetic--that contribute to nicotine dependence is a complex process, as we report on page 21. But the potential payoffs from new treatments in terms of health benefits (and developer profits) guarantees huge interest and promises rapid progress. In the meantime, the bigger bang per buck comes not from mechanistic biology and molecular therapies but from primary prevention programs.

A major boost to tobacco prevention in the United States is the State Tobacco Settlement, an extraordinary agreement signed in 1998 between tobacco companies and the states. The settlement's stand-out component is the payment amount: The companies will pay the states up to $250 billion (US) over 25 ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies